MUC1-CEA-ERBB2-telomerase-BIRC5-MAGEA1-RNA-vaccine - CureVac

Drug Profile

MUC1-CEA-ERBB2-telomerase-BIRC5-MAGEA1-RNA-vaccine - CureVac

Alternative Names: mRNA RCC vaccine - CureVac; mRNA renal cell carcinoma vaccine - CureVac; Mucin-1 carcinoembryonic antigen ERBB2 telomerase BIRC5 MAGEA1 RNA vaccine; RNAactive RCC vaccine - CureVac; RNAactive renal cell carcinoma vaccine - CureVac; TAA mRNA vaccine - CureVac

Latest Information Update: 31 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureVac
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Renal cancer

Most Recent Events

  • 13 Mar 2015 No development reported - Phase-I/II for Renal cancer in Germany (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top